{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:44:07Z","timestamp":1792115047557,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105649","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:54:18Z","timestamp":1791993258000},"page":"105649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When is 4\u202fGy enough? Defining dose sufficiency and durable control in indolent B-cell lymphoma"],"prefix":"10.1016","volume":"228","author":[{"given":"Yun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bichun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105649_bib1","article-title":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis","author":"Alhomoud","year":"2026","journal-title":"Haematologica 111(3) 876-891"},{"key":"10.1016\/j.critrevonc.2026.105649_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111327","article-title":"Low-dose radiotherapy for primary cutaneous indolent B-cell lymphomas: a multicenter retrospective study","volume":"215","author":"Al\u00ec","year":"2026","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105679","article-title":"Clinical use of circulating tumor DNA analysis in patients with lymphoma","volume":"156","author":"Bisig","year":"2025","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/cells9102287","article-title":"Targeting DNA repair, cell cycle, and tumor microenvironment in B cell lymphoma","volume":"9","author":"Br\u00f6ckelmann","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105649_bib5","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111515","article-title":"Optimizing low dose radiotherapy for indolent lymphomas: comparing 8 Gy in 2 fractions to 4 Gy in 2 fractions","volume":"219","author":"Burlile","year":"2026","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib7","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210012","article-title":"Efficacy of low-dose radiotherapy (2 Gy x 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas","volume":"94","author":"Cerrato","year":"2021","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib8","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.ijrobp.2010.10.013","article-title":"Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma","volume":"81","author":"Chan","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105649_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/hon.2865","article-title":"Low grade, indolent lymphomas of the head and neck: comparative toxicity of standard versus very low dose radiation therapy","volume":"39","author":"Chelius","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105649_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib12","article-title":"A phase II study of axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy","author":"ClinicalTrials.gov","year":"2026","journal-title":"Comb. Radiother. (RT) relapsed\/Refract. follicular Lymphoma (NCT06043323)"},{"key":"10.1016\/j.critrevonc.2026.105649_bib13","article-title":"A prospective phase III study comparing standard radiotherapy (24 Gy) with a PET response-guided very low dose (4 Gy) staged radiotherapy strategy for potentially curable","author":"ClinicalTrials.gov","year":"2026","journal-title":"indolent B-cell lymphomas (NCT07029217)"},{"key":"10.1016\/j.critrevonc.2026.105649_bib14","unstructured":"ClinicalTrials.gov, 2026. A phase II Trial Intermed. Radiat. dose Low. grade follicular Lymphoma (NCT05284825)https:\/\/clinicaltrials.gov\/study\/NCT05284825(accessed 16 May 2026).."},{"key":"10.1016\/j.critrevonc.2026.105649_bib15","unstructured":"ClinicalTrials.gov, 2026b. A phase II study of response adapted ultra low dose 4 Gy radiation for definitive therapy of marginal zone lymphoma (NCT05929612). https:\/\/clinicaltrials.gov\/study\/NCT05929612 (accessed 16 May 2026)."},{"key":"10.1016\/j.critrevonc.2026.105649_bib16","unstructured":"ClinicalTrials.gov, 2026e. Atezolizumab with or without low-dose local radiotherapy in relapsed or refractory advanced stage follicular lymphoma (NCT03465891). https:\/\/clinicaltrials.gov\/study\/NCT03465891 (accessed 16 May 2026)."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105649_bib17","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2024-208472","article-title":"A prospective clinical trial of Boom-Boom radiation as bridging therapy for patients with large B-cell lymphoma undergoing treatment with lisocabtagene maraleucel therapy","volume":"144","author":"D'Angelo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66767-9","article-title":"Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study","volume":"16","author":"de Boer","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105649_bib19","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105649_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105649_bib21","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(24)00133-9","article-title":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","volume":"11","author":"Gunther","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105649_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/10428194.2021.2010057","article-title":"Phase 1\/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma","volume":"63","author":"Halwani","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105649_bib24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105649_bib25","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1182\/bloodadvances.2025016505","article-title":"T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial","volume":"9","author":"Hawkes","year":"2025","journal-title":"Blood Adv."},{"issue":"S3","key":"10.1016\/j.critrevonc.2026.105649_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.70093_110","article-title":"High PFS with low in-field recurrences after low dose radiotherapy and obinutuzumab in early stage nodal follicular lymphoma: final results of the GAZAI study (GLA 2018-3)","volume":"43","author":"Herfarth","year":"2025","journal-title":"Hematol. Oncol."},{"issue":"S2","key":"10.1016\/j.critrevonc.2026.105649_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/hon.3163_142","article-title":"High rate of metabolic complete response after low dose radiotherapy and obinutuzumab in early-stage follicular lymphoma: initial results of the GAZAI study","volume":"41","author":"Herfarth","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib30","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105649_bib31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0360-3016(02)03050-X","article-title":"Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"54","author":"J\u00f3hannsson","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105649_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","article-title":"vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma","volume":"110","author":"Knoops","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105649_bib33","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood.V124.21.3092.3092","article-title":"Dose-escalated, intratumoral TLR9 agonist and low-dose radiation induce abscopal effects in follicular lymphoma","volume":"124","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"K\u00f6nig","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2026.105649_bib35","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105649_bib36","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/bjh.70137","article-title":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy","volume":"207","author":"Kuhnl","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1617087","article-title":"Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas","volume":"15","author":"Lake","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib38","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood.V128.22.2974.2974","article-title":"SD-101, a class C CpG-oligodeoxynucleotide TLR9 agonist, given with low dose radiation for untreated low grade B-cell lymphoma: interim results of a phase 1\/2 trial","volume":"128","author":"Levy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2020.02.636","article-title":"Abscopal regressions of lymphoma after involved-site radiation therapy confirmed by positron emission tomography","volume":"108","author":"MacManus","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105649_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105468","article-title":"Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma","volume":"110","author":"MacManus","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105649_bib42","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/bjh.70468","article-title":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: results from the phase II FLUORO study","volume":"208","author":"Martynchyk","year":"2026","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib43","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105649_bib44","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1158\/0008-5472.CAN-17-0082","article-title":"Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas","volume":"77","author":"O'Steen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105649_bib45","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood.2025032050","article-title":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis","volume":"147","author":"Oertel","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib46","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/cancers14174274","article-title":"Prospective study of 4 Gy radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma (FORMAL)","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105649_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2024.2112","article-title":"Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: a phase 2 nonrandomized controlled trial","volume":"10","author":"Pinnix","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib48","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1016\/S2352-3026(24)00143-1","article-title":"Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial","volume":"11","author":"Pulsoni","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib50","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105649_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ijrobp.2010.12.062","article-title":"Low-dose radiotherapy in indolent lymphoma","volume":"81","author":"Rossier","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105649_bib52","article-title":"Reduced-dose hypofractionated radiation therapy (3 Gy x 3 fractions) for indolent non-Hodgkin's lymphoma (POSEIDON): a multisite phase 2 randomized trial protocol","volume":"11","author":"Saifi","year":"2026","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib53","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1002\/cam4.2796","article-title":"Repeated courses of low-dose 2\u00d72 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas","volume":"9","author":"Saleh","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105649_bib54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-24-2770","article-title":"A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B-cell lymphoma highlights challenges in translation from mouse to human studies","volume":"31","author":"Shree","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105649_bib55","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/bloodadvances.2023011589","article-title":"A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis","volume":"8","author":"Shree","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105649_bib56","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2352-3026(25)00071-7","article-title":"Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Wang","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/aob-2025-1-55","article-title":"Low dose radiation in indolent lymphoma: from dose optimization to biological insight","volume":"11","author":"Wijetunga","year":"2026","journal-title":"Ann. Blood"},{"key":"10.1016\/j.critrevonc.2026.105649_bib58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105649_bib59","article-title":"Ultra-low-dose radiation for extranodal marginal zone lymphoma of the lung","volume":"9","author":"Wu","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105649_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:48:28Z","timestamp":1792111708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"alternative-id":["S1040842826005366"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105649","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When is 4\u202fGy enough? Defining dose sufficiency and durable control in indolent B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105649"}}